Foresite Capital under the leadership of its CEO, Jim Tananbaum, continues to make major strides improving medical care as well promoting healthcare entrepreneurship. The moves are in an effort to provide a better understanding of the challenges mental health patients’ face and facilitate the improvement of services offered to them. One of the firm’s recent moves is through partnering with other investors such as ARCH Venture Partners, One Mind Brain Health Impact Fund and Optum Ventures which has seen a donation of $14 to Mindstrong Health. The Series-A funding given to the start-up will enhance delivery of objective measures in an effort to improve outcomes for patients with mental disorders.
In other hits by the CEO and Managing Director of Foresite, he helped Sierra Ventures to set-up its healthcare service investment practice. Further, he leads several other biopharmaceutical investments such as Amerigroup (IPO) and Amira Pharmaceuticals (acquired Bristol Myers-Squib). Tananbaum has close to 25 years of experience in healthcare and it’s even more important to note that he manages $1.1 billion in assets at Foresite. Jim Tananbaum holds an M.B.A from Harvard Business School as well as an M.D from Harvard Medical School. His career in the biopharmaceutical industry started after he finished studies at Harvard Medical School where he immediately founded Geltex Pharmaceuticals, which generates $1 billion in revenues as of today. Other start-ups in his early life include Theravance, Inc which together has brought together a market cap of $2.75 billion together with Theravance Biopharma, Inc. Visit Crunchbase to know more.
His current leadership at Foresite has led to tremendous growth of the firm which is based in San Francisco and has another office in New York. The firm issues growth capital to start-ups and growing healthcare providers in both private and public markets. The success of the company largely comes from Tananbaum’s main focus on strategic operations as well as financial openings to grow the healthcare industry. The most recent achievement has been his listing on the Forbes Midas List of top 100 venture capitalists. His success comes for the third consecutive year from what can be termed as a capitalist who makes huge and early bets in providing leadership to tech companies as well as exceptional value for upcoming investors. It remains interesting to see the next steps by the Dr. Jim Tananbaum in healthcare entrepreneurship as well as other investments.